CTLA4 and pancreatic neoplasm: In pancreatic cancer, not responding to ICB therapy, a combination of anti-PD1 or anti-CTLA-4 checkpoint immunotherapy with PLX3397 improved anti-tumor immunity and led to the regression of established primary pancreatic tumors [92].